Datapoint: Lilly Scores Sweeping Label Expansion for Retevmo

The FDA last week granted a sweeping label expansion to Eli Lilly’s Retevmo, approving the drug for any cancers with locally advanced or metastatic solid tumors with rearranged during transfection (RET) gene fusion. The RET inhibitor will be available to adult patients whose tumors have not responded to prior treatments or have no alternative treatment options. Retevmo was first approved in 2020 for RET-fusion non-small cell lung cancer (NSCLC) and thyroid cancers. For these indications, the drug currently holds covered or better status for 93% of all insured lives under the pharmacy benefit. Just 6% of insured lives have preferred access to Retevmo, however, growing to 18% with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 9/26/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 1

Datapoint: FDA Approves Lexicon’s Heart Failure Drug

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 31

Datapoint: FDA Approves Celltrion’s Humira Biosimilar

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 30

Datapoint: Minnesota to Adopt Public Option Insurance

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today